CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop a novel immunotherapy targeting the tumor vasculature using engineered T cells. By understanding the interactions between these T cells and tumor blood vessels, it seeks to enhance tumor destruction while minimizing damage to normal tissues.
T cell engineering with chimeric antigen receptors has opened the door to effective immunotherapy.
CARs are fusion genes encoding receptors whose extracellular domain comprises a single chain variable fragment (scFv) antibody that binds to a tumour surface epitope, while the intracellular domain comprises the signalling module of CD3ζ along with powerful costimulatory domains (e.g.
CD28 and/or 4-1BB).
CARs are a major breakthrough, since they allow bypassing HLA restrictions or loss, and they ca…
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Switzerland, LAUSANNE
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
